Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer

Published:2018-04-01 Issue:4 Volume:4 Page:529
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Cremolini Chiara¹,Antoniotti Carlotta¹,Lonardi Sara²,Aprile Giuseppe³⁴,Bergamo Francesca²,Masi Gianluca¹,Grande Roberta⁵,Tonini Giuseppe⁶,Mescoli Claudia⁷,Cardellino Giovanni Gerardo³,Coltelli Luigi⁸,Salvatore Lisa¹⁹,Corsi Domenico Cristiano¹⁰,Lupi Cristiana¹¹,Gemma Donatello⁵,Ronzoni Monica¹²,Dell’Aquila Emanuela⁶,Marmorino Federica¹,Di Fabio Francesca¹³,Mancini Maria Laura¹⁴,Marcucci Lorenzo⁸,Fontanini Gabriella¹¹,Zagonel Vittorina²,Boni Luca¹⁵,Falcone Alfredo¹

Affiliation:

1. Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera–Universitaria Pisana, University of Pisa, Pisa, Italy

2. Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto–IRCCS, Padova, Italy

3. Department of Oncology, University and General Hospital, Udine, Italy

4. Department of Oncology, San Bortolo General Hospital, ULSS8 Berica, East District, Vicenza, Italy

5. Department of Medical Oncology, Hospital of Frosinone, Frosinone, Italy

6. Dipartimento di Oncologia Università Campus Bio-Medico di Roma, Rome, Italy

7. Surgical Pathology and Cytopathology Unit, Department of Medicine, University of Padua, Padova, Italy

8. Unit of Medical Oncology, Hospital Felice Lotti, Azienda Toscana Nord Ovest, Pontedera, Italy

9. Unit of Medical Oncology, Policlinico G. B. Rossi, Azienda Ospedaliera Integrata di Verona, Verona, Italy

10. Unit of Medical Oncology, Hospital San Giovanni Calibita Fatebenefratelli, Rome, Italy

11. Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy

12. Department of Oncology, Hospital San Raﬀaele IRCSS, Milan, Italy

13. Unit of Medical Oncology, Policlinico Sant’Orsola-Malpighi, Bologna, Italy

14. Department of Medical Oncology, Policlinico Umberto I Sapienza, University of Rome, Rome, Italy

15. Clinical Trials Coordinating Center, Toscano Cancer Institute, University Hospital Careggi, Florence, Italy

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients;Digestive and Liver Disease;2024-08

2. A two-stage maintenance trial of cetuximab-based treatment in RAS and BRAF wild-type unresectable metastatic colorectal cancer: a retrospective real-world study;Frontiers in Oncology;2024-07-23

3. Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer;World Journal of Gastrointestinal Oncology;2024-06-15

4. Constructing a prognostic model for colorectal cancer with synchronous liver metastases after preoperative chemotherapy: a study based on SEER and an external validation cohort;Clinical and Translational Oncology;2024-06-04

5. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial;PLOS Medicine;2024-05-10